Fierce Pharma Biopharma News & Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
2024 forecast: Big Pharma reworks China strategy, and ... - Fierce …
Dec 22, 2023 · Big Pharma companies have often talked about the major opportunities that await in China. But as price cuts play out and internal priorities shift, multinational companies are …
Amid Biden admin's drug-pricing push, Big Pharma kicks off 2024 …
Jan 2, 2024 · While public and political scrutiny around drug pricing has reached a fever pitch in the wake of 2022’s Inflation Reduction Act (IRA), that hasn’t stopped pharma majors from …
2023 forecast: FDA revamps cancer drug approvals - Fierce Pharma
Dec 21, 2022 · Recent regulatory changes could cause a “massive delay” in cancer drug approvals, but Big Pharma is willing to cooperate with the FDA, SVB Securities' Daina …
Big Pharma Companies Ranked by Revenue 2022 - Fierce Pharma
Apr 18, 2023 · The Big Pharma's sales gradually increased from $40.8 billion in 2018 to $41.6 billion in 2020. | 2022 was all about a return to normalcy from the COVID-19 pandemic.
Top 20 pharma companies by 2023 revenue - Fierce Pharma
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue.
Pharma | Fierce Pharma
Oct 14, 2024 · Pharma Former FDA chief Gottlieb weighs in on RFK Jr. pick for HHS The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.
Hey, big spender: Pharma's $6.6B TV ad outlay outranks most …
May 15, 2019 · Pharma is the fourth-largest spender on TV ads in the U.S., with $6.6 billion spent over the past year.
Big Pharmas finally strike with GSK, Merck acquisitions - Fierce …
Apr 18, 2023 · Then GSK struck Tuesday, offering $2 billion for Bellus Health to challenge its fellow pharma dealmaker in the cough market.
Trump won a second term. What does it mean for biopharma?
Nov 6, 2024 · Now with the Inflation Reduction Act in play, what's to come for pharma under a Trump administration?